NCT05133076View on ClinicalTrials.gov

Safety and Preliminary Efficacy of BGP345A in Constipation Due to Opioid-based Medications

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

January 20, 2022

Primary Completion Date

December 12, 2024

Study Completion Date

December 12, 2024

Conditions
Opioid-Induced Constipation
Interventions
BIOLOGICAL

Lactobacillus gasseri BGP345A

Active and placebo capsules for oral use

BIOLOGICAL

Placebo

Placebo

Trial Locations (4)

44800

CHU DE NANTES (Hôpital Nord Laennec), Saint-Herblain

59322

CH de Valenciennes, Valenciennes

75014

Groupe hospitalier Saint-Joseph, Paris

80054

CHU d'Amiens, Amiens

Sponsors

Lead Sponsor

BioGaia Pharma AB

Collaborators (1)

BioFortis
All Listed Sponsors
collaborator

BioFortis

OTHER

lead

BioGaia Pharma AB

INDUSTRY

NCT05133076 - Safety and Preliminary Efficacy of BGP345A in Constipation Due to Opioid-based Medications | Biotech Hunter | Biotech Hunter